BioNTech SE (BNTX) on Wednesday announced that 184 million shares of CureVac, which is about 81.74 percent of the total shares, were successfully submitted by the December 3 deadline.
This meets the minimum requirement for their exchange offer. Now, BioNTech will provide ADSs or cash for any fractional ADSs to the shareholders who participated, and they've also opened up another offering period until December 18.
Once that period wraps up, they'll go ahead with a post-offer reorganization.
BNTX is currently trading at $97.01, up $0.90 or 0.94 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.